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thrombosis among patients treated with the ABSORB.
Furthermore, in the largest of these trials (ABSORB-III), treatment of small vessels (#2.25 mm) was associated with a higher occurrence of target-lesion failure and device thrombosis.
Although randomized trials provide the highest quality scientific data, their inclusion/exclusion criteria frequently limit the applicability of their results to the broader population of our daily practice. 
